Celldex Therapeutics announced it will cease development of barzolvolimab for eosinophilic esophagitis (EoE) despite meeting primary phase 2 endpoints related to mast cell depletion in the gastrointestinal tract. The antibody’s inability to improve clinical symptomatology suggests that mast cells may not be the principal drivers of EoE pathophysiology. This strategic decision refocuses Celldex's pipeline efforts as it evaluates next steps for the antibody in related indications.